HCA Healthcare (NYSE:HCA) Given “Overweight” Rating at Cantor Fitzgerald

HCA Healthcare (NYSE:HCA)‘s stock had its “overweight” rating restated by investment analysts at Cantor Fitzgerald in a research report issued on Tuesday, Benzinga reports. They currently have a $392.00 target price on the stock. Cantor Fitzgerald’s target price would suggest a potential downside of 3.18% from the stock’s current price.

A number of other research firms also recently issued reports on HCA. Truist Financial lifted their target price on HCA Healthcare from $390.00 to $430.00 and gave the company a “buy” rating in a research report on Monday, August 19th. UBS Group boosted their target price on shares of HCA Healthcare from $405.00 to $438.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Royal Bank of Canada upped their target price on shares of HCA Healthcare from $378.00 to $405.00 and gave the company an “outperform” rating in a report on Friday, August 23rd. Morgan Stanley began coverage on HCA Healthcare in a research note on Tuesday, September 3rd. They issued an “equal weight” rating and a $427.00 price objective on the stock. Finally, StockNews.com upgraded HCA Healthcare from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 1st. Five analysts have rated the stock with a hold rating, fourteen have issued a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $359.89.

HCA Healthcare Stock Down 0.4 %

NYSE HCA traded down $1.57 on Tuesday, reaching $404.86. The company had a trading volume of 159,149 shares, compared to its average volume of 1,130,916. The firm has a market capitalization of $106.04 billion, a price-to-earnings ratio of 20.18, a price-to-earnings-growth ratio of 1.52 and a beta of 1.67. The company’s fifty day moving average is $380.53 and its 200-day moving average is $343.58. HCA Healthcare has a 1-year low of $215.96 and a 1-year high of $409.42. The company has a debt-to-equity ratio of 27.11, a quick ratio of 0.94 and a current ratio of 1.06.

HCA Healthcare (NYSE:HCA) last released its quarterly earnings results on Tuesday, July 23rd. The company reported $5.50 earnings per share for the quarter, topping analysts’ consensus estimates of $4.97 by $0.53. The firm had revenue of $17.49 billion during the quarter, compared to the consensus estimate of $17.05 billion. HCA Healthcare had a return on equity of 553.13% and a net margin of 8.40%. The business’s revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $4.29 EPS. On average, research analysts forecast that HCA Healthcare will post 22.46 earnings per share for the current fiscal year.

Insider Activity at HCA Healthcare

In other news, EVP Michael S. Cuffe sold 8,358 shares of the business’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $385.42, for a total transaction of $3,221,340.36. Following the completion of the transaction, the executive vice president now owns 29,678 shares of the company’s stock, valued at approximately $11,438,494.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other HCA Healthcare news, SVP Kathleen M. Whalen sold 2,987 shares of the stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $363.51, for a total value of $1,085,804.37. Following the completion of the transaction, the senior vice president now directly owns 9,454 shares in the company, valued at $3,436,623.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael S. Cuffe sold 8,358 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $385.42, for a total value of $3,221,340.36. Following the completion of the transaction, the executive vice president now directly owns 29,678 shares of the company’s stock, valued at approximately $11,438,494.76. The disclosure for this sale can be found here. Insiders have sold 17,202 shares of company stock valued at $6,407,273 over the last three months. 1.60% of the stock is owned by insiders.

Hedge Funds Weigh In On HCA Healthcare

Several large investors have recently modified their holdings of HCA. University of Texas Texas AM Investment Management Co. raised its position in HCA Healthcare by 28.7% during the 2nd quarter. University of Texas Texas AM Investment Management Co. now owns 5,562 shares of the company’s stock worth $1,787,000 after purchasing an additional 1,241 shares during the last quarter. Sanctuary Advisors LLC acquired a new position in shares of HCA Healthcare in the second quarter worth approximately $7,110,000. 3Chopt Investment Partners LLC acquired a new stake in HCA Healthcare during the 2nd quarter valued at approximately $275,000. Granite Bay Wealth Management LLC bought a new stake in shares of HCA Healthcare in the 2nd quarter valued at $733,000. Finally, Advisory Alpha LLC raised its stake in HCA Healthcare by 55.8% during the second quarter. Advisory Alpha LLC now owns 949 shares of the company’s stock worth $305,000 after buying an additional 340 shares during the last quarter. Institutional investors own 62.73% of the company’s stock.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.